ALR Technologies Announces Development Partnership Agreement With Insulin Algorithms; Successful Integration of the Two

ALR Technologies Announces Development Partnership Agreement With Insulin 
Algorithms; Successful Integration of the Two Technology
Platforms Could Lead to Near-Instantaneous Insulin Dosage
Consultation and Adjustment 
RICHMOND, VA -- (Marketwired) -- 11/05/13 --  ALR Technologies
(OTCBB: ALRT) and Insulin Algorithms (InsulinAlgo) announced a
technology partnership that would integrate Insulin Algorithm's
insulin dosage adjustment software with ALRT's Health-e-Connect
remote monitoring platform. An integration of the two technology
platforms would create a revolutionary system that would allow
patients to remotely upload their blood glucose data to the ALRT
platform and then, within seconds, the patient's physician could be
provided with an insulin dosage recommendation electronically when
the patient's blood glucose data and patient profile were run through
the Insulin Algorithm software. Proper dosing of insulin is one of
the most important and challenging tasks in diabetes care and an
effective system to dose insulin would reduce adverse events, improve
outcomes and reduce the costs of care for patients living with
diabetes.  
ALRT's platform has received FDA 510(k) clearance but any commercial
use of Insulin Algorithms' software will require additional U.S. Food
and Drug Administration regulatory clearance. Under the agreement,
ALRT will have access to the InsulinAlgo software to begin the
integration process while InsulinAlgo's FDA clearance is pending.
Once integrated and tested, and after final FDA clearance, the
ALRT-InsulinAlgo system will be made available to the commercial
marketplace both in the U.S. and internationally.  
Insulin Algorithm's Founder and Chief Medical Officer, Dr. Mayer B.
Davidson, said: "We are very excited about our partnership with ALRT.
I have spent a career studying how to properly dose insulin and our
algorithms embody that experience. This partnership with ALRT
represents the potential to offer our expertise to many providers
quickly and electronically, without the inconvenience of paper
logbooks and unnecessary additional physician visits. We hope to
serve as an experienced resource for those physicians who are on the
front line of diabetes care." 
ALRT's CEO Sidney Chan said: "We are honored to partner with Insulin
Algorithms as its founder is one of the world's most renowned experts
on the proper use of insulin. As the global pandemic has spread from
the developed world to the emerging economies, we believe there is an
urgent need to provide physicians and patients with the benefit of
the very best thinking about proper insulin dosing. Our partnership
has the potential to bring this knowledge as quickly and efficiently
as a text message. We believe there is a worldwide market for this
tool." 
About Insulin Algorithms 
Based on Dr. Mayer B. Davidson's 35 years of diabetes research,
Insulin Algorithms has created software that will make specific
insulin dosage adjustment recommendations based on the patient's
current physical characteristics, insulin regimen, and the hundreds
of individual readings they have every month. Dr. Davidson is
Professor of Medicine at both the David Geffen School of Medicine at
UCLA and Charles R. Drew University. Dr. Davidson was President of
the American Diabetes Association in 1997-1998. A renowned researcher
and speaker on type 2 diabetes and insulin resistance, Dr. Davidson
has presented hundreds of lectures nationally and internationally. He
has served on the Editorial Boards of Diabetes Care, Diabetes
Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine,
Geriatrics and the Journal of Clinical Endocrinology and Metabolism
and was a Consulting Editor of Hippocrates and an Associate Editor of
Endo Trends. He currently serves on the Editorial Board of Diabetes
Research & Clinical Practice. Further, Dr. Davidson was the Founding
Editor of Current Diabetes Reports and was the Editor-in-Chief of
Diabetes Care from 2002 through 2006, the leading clinical journal
for the diabetes community. Dr. Davidson's contributions to the
medical literature include 3 books on diabetes care, 168 scientific
papers, 31 book chapters, 59 reviews and 54 editorials and invited
articles. More information about Insulin Algorithms, Inc. can be
found at www.insulinalgorithms.com. 
About ALR Technologies Inc. 
ALR Technologies is a medical device company providing remote
monitoring and care facilitation for patients with chronic diseases.
ALRT has developed the FDA-cleared and HIPAA compliant
Health-e-Connect System that collects data from blood glucose meters
and uploads to a secure website. Trained Facilitators use the System
to effect efficiency of care among patients, clinicians and
caregivers to improve outcomes and assist health plans to optimize
their HEDIS goals. Currently, the Company is focused on diabetes and
will expand its services to cover other chronic diseases anchored on
verifiable data. More information about ALR Technologies, Inc. can be
found at www.alrt.com. 
This release contains certain "forward-looking statements" relating
to ALR Technologies' business, and these statements reflect the
current views of ALR Technologies with respect to future events and
are subject to certain risks, uncertainties and assumptions. When
used, the words "estimate", "expect", "anticipate", "believe" and
similar expressions are intended to identify such forward-looking
statements. There are many factors that could cause the actual
results, performance or achievements of ALR Technologies and its
products to be materially different from any future results,
performances or achievements that may be expressed or implied by such
forward-looking statements. Further management discussions of risks
and uncertainties can be found in the company's quarterly filings
with the Securities Exchange 
Contact: 
Bill Smith
bill.smith@alrt.com
203.762.1073